PROTACs: A novel strategy for cancer drug discovery and development
Abstract Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: a small molecule that binds to a target protein, an E3 ligase ligand (consisting of an E3...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2023-06-01
|
| Серія: | MedComm |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/mco2.290 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|